Leading companies in the burn market include Medical Developments International, Cumberland Pharmaceuticals, Janssen Research and Development, and Cephalon.
DelveInsight's latest report, " Burn Injuries Market Insights, Epidemiology, and Market Forecast – 2034 " , provides a comprehensive analysis of burn injuries with detailed insights into historical and projected epidemiological trends, market dynamics, and treatment landscape in the US, EU4 (Germany, Spain, Italy, France, UK), and Japan.
To explore insights into the burn injury market outlook, treatment trends, medication uptake, and epidemiology, click here: Burn Pain Market Forecast
The burnt pain market is projected to expand at a significant CAGR during the forecast period (2020-2034).
In August 2024, MediWound Ltd. (Nasdaq: MDWD) received FDA approval of NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients with deep and full-thickness burns, from newborns to 18 years of age. This marks a major milestone as NexoBrid is now approved for all age groups in the U.S., similar to its approval in the EU and Japan.
The United States is expected to lead the market in 2023 with a valuation of $140 million and continue its dominance until 2034.
Within the EU4 region, Germany and the UK were followed by France with market volumes exceeding $20 million in 2023. Italy recorded the lowest market share in the region for the same period.
Opioid analgesics dominate current treatment practice in both inpatient and outpatient settings, with the market value estimated to reach $130 million in 2023.
More than 2 million burn injuries will be reported in the United States in 2023, and this number is predicted to increase by 2034.
Approximately 400,000 burn care cases requiring pain management will be recorded in the United States in 2023, and are expected to change over the forecast period.
The majority of burn pain cases across the 7MM are in male patients, with approximately 290,000 male patients and 260,000 female patients in the United States in 2023.
Major burn treatments include methoxyflurane (PENTHROX), Caldolor, JNJ-42160443, and ACTIQ.
Burn market segmentation by etiology includes flame, contact, thermal, electrical, chemical, and others.
The burn injury market is poised for growth due to the increasing prevalence and awareness of the disease, as well as the expected launch of several pipeline products that will significantly change market trends.
Overview of Burn Pain
A burn is an injury to organic tissue caused primarily by heat, electricity, radiation, chemicals, friction, or radioactivity.
Get your free sample of Burn Pain Market Report now: https://www.delveinsight.com/sample-request/burn-pain-market
Epidemiology of burns
Based on key research and expert insights, this section explores the past, current and forecast trends in burn injury epidemiology across the 7MM from 2020 to 2034. It also includes a detailed breakdown of diagnosed patient populations and expected future trends.
Epidemiological segmentation of burn pain includes:
Total Burn Prevalence
Prevalent cases by severity
Prevalence by gender
Diagnosed episodic and chronic cases
Download the report to learn about the factors shaping burn injury epidemiology trends: Burn Injury Epidemiology Forecast
Drug uptake and pipeline development
This section provides an overview of the uptake rates of existing and upcoming treatments in the burn field, including patient adoption, drug sales, and competitive analysis.
The therapeutic landscape review helps identify the fastest growing drugs and explains their widespread use. It also benchmarks medicines based on market share and uptake.
Additionally, the report covers all stages of development activity including strategic alliances, licensing, and mergers for novel burn therapeutics.
Main burn treatment methods and developers
Methoxyflurane (PENTHROX) – Medical Development International
Kaldor – Cumberland Pharmaceuticals
JNJ-42160443 – Janssen Research and Development
Actic – Cephalon
Find out which treatments are expected to lead the Burn Treatment market .
Market Strengths and Opportunities
Strengths: Rising incidence of burns is predicted to drive demand for treatment, opening up new market potential.
Opportunity: The growing need for pharmacological treatments for burn pain represents a huge opportunity for budding pharmaceutical companies.
Scope of the Burn Injury Market Report
Study period: 2020-2034
Coverage: 7MM (US, EU5, Japan)
Key Players: Medical Developments International, Cumberland Pharmaceuticals, Janssen R&D, Cephalon, etc.
Main treatments: Methoxyflurane (PENTHROX), Caldrol, JNJ-42160443, ACTIQ, etc.
The assessment includes: marketed and pipeline therapies, market drivers and barriers
Analysis tools: SWOT, PESTLE, BCG matrix, Porter's five forces
Additional Coverage: Unmet Need, KOL Insights, and the Access and Reimbursement Landscape
For more information about companies in this field, please visit Burn Clinical Trials and Treatment Evaluations .
About DelveInsight
DelveInsight is a leading healthcare consulting and market research firm focused on life sciences. It supports pharmaceutical companies by providing customized end-to-end solutions to improve business performance. The company also offers strategic healthcare consulting services that help accelerate market entry and overcome operational challenges.
Contact Information
Name: Kanishq
Email: kkumar@delveinsight.com